This biopharmaceutical firm shows promise.
I'm bullish long term, but for now, can BMY generate follow-through buying?
Let's check the charts and indicators of the IBB.
Here's what aggressive traders could do now.
This stock is in a technical state of weakness and add that to the eroding fundamentals.
Here's how traders can play the stock.
Buyers of the biopharmaceutical's stock are being more aggressive than sellers.
In light of the stock market's weakness, CYTK has shown impressive strength.
The shares of the biotech company appear to be finding a bottom but could use more sideways action to create a better base.
I expect biotech M&A activity to pick up in the back half of 2022.